Literature DB >> 1767806

Pharmacodynamics and pharmacokinetics of antibiotics with special reference to the fluoroquinolones.

M N Dudley1.   

Abstract

The pharmacodynamic and pharmacokinetic properties of antibiotics have received increased attention in recent years, leading to optimization of dosage regimens. In view of these characteristics, certain fluoroquinolones may prove advantageous compared with other antimicrobials for treatment of selected infections. Several new fluoroquinolone antimicrobial agents have potency equal to or greater than that of beta-lactam antibiotics against gram-negative aerobic bacilli, including Pseudomonas aeruginosa. In vitro bactericidal activity of these compounds is more rapid than that of the beta-lactams, often resembling that for the aminoglycosides. Like the aminoglycosides, but in contrast to the beta-lactams, fluoroquinolones exert a significant in vitro postantibiotic effect against some strains of P. aeruginosa and Enterobacteriaceae. However, unlike many beta-lactam and aminoglycoside antimicrobial agents that have similar in vitro activity, fluoroquinolones are often effective both after oral and parenteral administration. Important pharmacokinetic properties of fluoroquinolones include differences in the extent and variability in oral absorption and clearance, which determine the extent of in vivo exposure to drug. Drugs and dosage regimens that result in a high degree of exposure, particularly high peak levels of drug, may be preferable because of a greater extent of bacterial killing and less selection of drug-resistant bacteria.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1767806     DOI: 10.1016/0002-9343(91)90311-k

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  29 in total

Review 1.  Use of newer quinolones for the treatment of intraabdominal infections: focus on clinafloxacin.

Authors:  C E Nord
Journal:  Infection       Date:  1999 May-Jun       Impact factor: 3.553

2.  Pharmacokinetics of pefloxacin in goats after intravenous or oral administration.

Authors:  J K Malik; G S Rao; S Ramesh; S Muruganandan; H C Tripathi; D C Shukla
Journal:  Vet Res Commun       Date:  2002-02       Impact factor: 2.459

3.  Pharmacodynamics of trovafloxacin, ofloxacin, and ciprofloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model.

Authors:  P D Lister; C C Sanders
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

4.  Pharmacokinetics (PK), pharmacodynamics (PD), and PK-PD integration of danofloxacin in sheep biological fluids.

Authors:  F Shojaee Aliabadi; M F Landoni; P Lees
Journal:  Antimicrob Agents Chemother       Date:  2003-02       Impact factor: 5.191

5.  Pharmacodynamics of gatifloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model: impact of area under the curve/MIC ratios on eradication.

Authors:  Philip D Lister
Journal:  Antimicrob Agents Chemother       Date:  2002-01       Impact factor: 5.191

6.  The population dynamics of antimicrobial chemotherapy.

Authors:  M Lipsitch; B R Levin
Journal:  Antimicrob Agents Chemother       Date:  1997-02       Impact factor: 5.191

7.  Antibiotic exposure and its relationship to postantibiotic effect and bactericidal activity: constant versus exponentially decreasing tobramycin concentrations against Pseudomonas aeruginosa.

Authors:  R C Li; Z Y Zhu; S W Lee; K Raymond; J M Ling; A F Cheng
Journal:  Antimicrob Agents Chemother       Date:  1997-08       Impact factor: 5.191

8.  Ciprofloxacin in polyethylene glycol-coated liposomes: efficacy in rat models of acute or chronic Pseudomonas aeruginosa infection.

Authors:  Irma A J M Bakker-Woudenberg; Marian T ten Kate; Luke Guo; Peter Working; Johan W Mouton
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

9.  Fluoroquinolones in the Treatment of Meningitis.

Authors:  Philippe Cottagnoud; Martin G. Täuber
Journal:  Curr Infect Dis Rep       Date:  2003-08       Impact factor: 3.725

10.  Dose ranging and fractionation of intravenous ciprofloxacin against Pseudomonas aeruginosa and Staphylococcus aureus in an in vitro model of infection.

Authors:  C R Marchbanks; J R McKiel; D H Gilbert; N J Robillard; B Painter; S H Zinner; M N Dudley
Journal:  Antimicrob Agents Chemother       Date:  1993-09       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.